Company Overview of Virobay Inc.
Virobay Inc. engages in the design, synthesis, and development of small molecule inhibitors of cysteine proteases for the treatment of autoimmune diseases, neuropathic pain, liver diseases, and cancer. It offers VBY-129, VBY-891, VBY-036, VBY-285, VBY-376, VBY-825 inhibitors against cathespin protease, liver fibrosis, atherosclerosis, cardiovascular disorders, and other disease indications. Virobay Inc. was founded in 2006 and is headquartered in Menlo Park, California with contract research and manufacturing facilities worldwide.
1490 O’Brien Drive
Menlo Park, CA 94025
Founded in 2006
Key Executives for Virobay Inc.
Virobay Inc. Key Developments
Similar Private Companies By Industry
|Sky Growth Acquisition Corporation||United States|
|Ally Pharma US, Inc.||United States|
|Genoa Pharmaceuticals, Inc.||United States|
|Pecos Labs Inc.||United States|
|Warner Chilcott Company, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Greater Houston Partnership||United States|
Post a JobJobs
- Montgomeryville, PA | PulsecxPosted: Apr 20
- Elkhorn, NE | NescoPosted: Apr 23
- Allentown, PA | Publicis Touchpoint SolutionsPosted: Apr 23
- Remote, OR | ForestPosted: Apr 23
Sponsored Financial Commentaries
To contact Virobay Inc., please visit www.virobayinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.